• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Flora Growth Announces Results of Annual Meeting of Shareholders; Appointment of Brandon Konigsberg to Board of Directors

    7/6/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FLGC alert in real time by email

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today that at the Company's annual meeting of shareholders held on July 5, 2022, the Company's shareholders voted in favor of all of the proposals submitted for their approval. The four proposals that were approved included (i) the election of seven members to the Company's Board of Directors (the "Board"), (ii) the re-appointment of Davidson & Company LLP as the Company's auditors, (iii) the approval of the Company's 2022 Incentive Compensation Plan and (iv) the approval of new bylaw 1-A. For the complete voting results with respect to each of the proposals set forth above, reference is made to the Company's Report on Form 6-K, filed with the Securities Exchange Commission on July 6, 2022.

    In addition to the re-election of the Company's six incumbent directors, the Company's shareholders also elected Brandon Konigsberg to serve on the Board. In addition to his duties as a Board member, Konigsberg will serve as Chair of the Audit Committee and as a member of the Compensation Committee.

    "The addition of Mr. Konigsberg to our Board is further testament to our ongoing commitment to fiscal discipline and sound governance. He brings with him exceptional experience in the fields of finance and operations and will assist in helping our organization achieve rapid financial growth and maximize our shareholder value," said Luis Merchan, Flora's Chairman and CEO. "We are pleased to welcome Mr. Konigsberg as a valued member of our team and look forward to his contributions."

    Konigsberg is a seasoned leader in finance and will focus on Flora's key growth drivers to advance the Company's global expansion. Konigsberg is a former executive of JP Morgan Chase ("JPMC"), and has held various leadership roles, serving as CFO and COO for various growing and turnaround business units. After 24 years at JPMC, Konigsberg retired to focus full-time on consulting, advising and entrepreneurial endeavors. He is currently the President and CFO of Fynn, an education financing company he joined as a consultant in 2021. Konigsberg also holds various board director, chair and audit committee memberships including Chicago Atlantic Real Estate Finance, Inc., a specialty mortgage REIT focused on lending to cannabis companies since its IPO in 2021.

    "I am excited to be joining Flora's Board of Directors and look forward to assisting the management team as the Company continues to make progress on its strategic financial plans," Konigsberg said. "As an executive and entrepreneur operating for many years in finance and treasury, I look forward to taking on challenges and opportunities that lie ahead for our Board and the Flora organization."

    About Flora Growth Corp.

    Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the most extensive outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands, and life sciences divisions. Visit www.floragrowth.com or follow @floragrowthcorp on social media for more information.

    Forward-Looking Statements

    This press release contains ‘‘forward-looking statements,'' as defined by federal securities laws. Forward-looking statements reflect Flora's current expectations and projections about future events at the time, and thus involve uncertainty and risk. The words "believe," "expect," "anticipate," "will," "could," "would," "should," "may," "plan," "estimate," "intend," "predict," "potential," "continue," and the negatives of these words and other similar expressions generally identify forward looking statements. Such forward-looking statements are subject to various risks and uncertainties, including those described under the section entitled "Risk Factors" in Flora's Annual Report on Form 20-F filed with the SEC on May 9, 2022, as such factors may be updated from time to time in Flora's periodic filings with the SEC, which are accessible on the SEC's website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Flora's filings with the SEC. While forward-looking statements reflect Flora's good faith beliefs, they are not guarantees of future performance. Flora disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Flora (or to third parties making the forward-looking statements).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005276/en/

    Get the next $FLGC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FLGC

    DatePrice TargetRatingAnalyst
    11/25/2024$4.00Buy
    Aegis Capital
    10/13/2021$10.00Buy
    Roth Capital
    6/23/2021$6.00Buy
    MKM Partners
    More analyst ratings

    $FLGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Flora Growth Corp. Closes Acquisition of Australian Vaporizers

      Fort Lauderdale, Florida--(Newsfile Corp. - June 5, 2024) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company") has entered into a share purchase agreement (the "Agreement") to acquire of all of the issued and outstanding shares of Australian Vaporizers Pty Limited ("Australian Vaporizers") in exchange for 550,000 Flora common shares, valued at $0.7 million based on the closing price of Flora's common shares on June 3, 2024, subject to working capital adjustments. The transaction closed on June 4, 2024. Australian Vaporizers was founded in 2010 and has become one of the largest online retailers of vaporizers, hardware, and accessories in Australia. It is an online expert for aromathe

      6/5/24 9:20:00 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifeist Sells Australian Vapes

      TORONTO, June 05, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV:LFST) (FRANKFURT: M5B) (OTC:LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today announced the sale of Australian Vaporizers Pty Ltd. ("Aussie Vapes"), its wholly owned Australian subsidiary to Flora Growth Corp. (NASDAQ:FLGC) ("Flora"), a U.S.-based consumer-packaged goods and pharmaceutical distributor serving all 50 states and 28 countries. The sale was completed through a share purchase agreement (the "SPA") entered into between Lifeist, as vendor, and Flora Growth Corp, as purchaser, purs

      6/5/24 7:00:00 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TSX Venture Exchange Stock Maintenance Bulletins

      VANCOUVER, BC, June 4, 2024 /CNW/ - TSX VENTURE COMPANIES BULLETIN V2024-1678 CEAPRO INC. ("CZO")BULLETIN TYPE: Plan of Arrangement, Remain Halted, DelistBULLETIN DATE: June 4, 2024TSX Venture Tier 2 Company  TSX Venture Exchange (the "Exchange") has accepted for filing documentation in connection with an arrangement agreement dated December 14, 2023, as amended on January 16, 2024, between Ceapro Inc. ("Ceapro") and Aeterna Zentaris Inc. ("Aeterna"), pursuant to which Aeterna acquired all of the issued and outstanding common shares of Ceapro by way of a plan of arrangement under the Canada Business Corporations Act (the "Arrangement"). Under the terms of the Arrangement, Ceapro shareholder

      6/4/24 11:24:00 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Starke Clifford bought $6,455 worth of shares (6,795 units at $0.95), increasing direct ownership by 13,324% to 6,846 units (SEC Form 4)

      4 - Flora Growth Corp. (0001790169) (Issuer)

      9/17/24 10:17:39 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wolkin Harold bought $24,255 worth of shares (25,000 units at $0.97) (SEC Form 4)

      4 - Flora Growth Corp. (0001790169) (Issuer)

      9/11/24 5:43:51 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Starke Clifford bought $48 worth of shares (51 units at $0.95), increasing direct ownership by 0.01% to 474,046 units (SEC Form 4)

      4 - Flora Growth Corp. (0001790169) (Issuer)

      9/6/24 5:25:10 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $FLGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $FLGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Director Woo Edward was granted 50,000 shares, increasing direct ownership by 59% to 134,698 units (SEC Form 4)

      4 - Flora Growth Corp. (0001790169) (Issuer)

      12/17/24 10:22:07 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wolkin Harold

      4 - Flora Growth Corp. (0001790169) (Issuer)

      12/17/24 10:19:00 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CFO Vaiman Dany

      4 - Flora Growth Corp. (0001790169) (Issuer)

      12/17/24 10:01:07 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital initiated coverage on Flora Growth with a new price target

      Aegis Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $4.00

      11/25/24 8:07:10 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital initiated coverage on Flora Growth with a new price target

      Roth Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $10.00

      10/13/21 9:00:51 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MKM Partners initiated coverage on Flora Growth with a new price target

      MKM Partners initiated coverage of Flora Growth with a rating of Buy and set a new price target of $6.00

      6/23/21 5:36:01 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

      SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

      12/17/24 8:02:53 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

      SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

      12/17/24 8:01:40 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Flora Growth Corp.

      SC 13G/A - Flora Growth Corp. (0001790169) (Subject)

      11/14/24 2:24:54 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLGC
    SEC Filings

    See more
    • SEC Form S-3 filed by Flora Growth Corp.

      S-3 - Flora Growth Corp. (0001790169) (Filer)

      5/14/25 4:02:08 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Flora Growth Corp.

      10-Q - Flora Growth Corp. (0001790169) (Filer)

      5/13/25 4:56:00 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Flora Growth Corp.

      D - Flora Growth Corp. (0001790169) (Filer)

      5/8/25 7:36:37 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FLGC
    Leadership Updates

    Live Leadership Updates

    See more
    • Flora Growth Corp. Appoints Clifford Starke as Chief Executive Officer and Dany Vaiman as Chief Financial Officer; Regains Compliance with NASDAQ Minimum Bid Requirement

      Fort Lauderdale, Florida--(Newsfile Corp. - June 27, 2023) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a consumer-packaged goods leader serving all 50 states with 15,000+ points of distribution around the world and a pharmaceutical distributor in 28 countries, announced today that Clifford Starke has been appointed as Chief Executive Officer to lead its global operations and Dany Vaiman has been appointed as Chief Financial Officer. Mr. Starke, who previously served as President of the Company, takes over for Hussein Rakine, who resigned as CEO but will remain on the Company's Board of Directors. Mr. Rakine expressed his confidence in the appointment, stating, "Clifford's

      6/27/23 4:05:00 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flora Growth Corp. Announces the Appointment of Hussein Rakine as CEO and Member of the Board of Directors

      Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company") a leading cultivator, manufacturer and distributor of global cannabis products and brands, today announced that its board of directors (the "Board") accepted the resignation of Luis Merchan as Chairman of the Board and the Company's Chief Executive Officer (CEO). To fill the vacancies created by Mr. Merchan's resignation, the Board has appointed JustCBD founder, Hussein Rakine, as CEO and member of the board of directors. Of the appointment, former-Chairman and CEO, Luis Merchan said, "At Flora we have consistently placed human capital as a critical part of our M&A strategy. That's why today we are honored to have the former foun

      4/18/23 4:05:00 PM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CBD Oil Market to Hit Nearly US$137 Billion by 2029

      FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 23, 2022 /PRNewswire/ -- The CBD oil market is expected to witness an astounding CAGR of 38.90% from 2021 until 2029, climbing from $9.86 billion to $136.64 billion. There are several reasons behind the projected growth such a growing number of CBD-infused skincare products, increased use of THC and CBD in pain management and treatment, rising sales in both retail stores and online, expanding research, and increasing demand for ingestible products. Governments around the world have also begun opening up more doors for CBD, with a recent Health Canada report suggesting legal framework to broaden retail CBD sales across

      8/23/22 8:50:00 AM ET
      $CGC
      $CRON
      $FLGC
      $OGI
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $FLGC
    Financials

    Live finance-specific insights

    See more
    • Flora Growth Sets Third Quarter 2022 Conference Call for November 28, 2022, at 4:30 P.M. ET

      Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, will host its third quarter 2022 earnings call via webcast on Monday, November 28 at 4:30 p.m. ET. During the webcast, Flora management will deliver financial and operational results for the third quarter ended September 30, 2022, and provide updates on Flora's commercial wholesale operations, house of brands and life sciences division strategies. Following the webcast, Flora management will open the call to analysts, media and investors in a Q&A format. Live Webcast Details Date: Monday, November 28, 2022 Time: 4:30 p.m. ET

      11/21/22 7:05:00 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flora Growth to Host Webcast Discussing M&A Activity and International Market Opportunities - Wednesday, October 26, 2022

      Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today that the Company will be hosting an analyst call on Wednesday, October 26, 2022, at 02:00 p.m. EST via webcast to discuss Flora Growth's recent M&A activity and strategic growth opportunities. The conference call and live webcast will invite analysts to pose questions to Flora and Franchise Global Health's leadership teams regarding the recent announcement of the definitive agreement of acquisition between the two companies and the opportunities within the cannabis industry on the global stage. To access this ca

      10/25/22 7:05:00 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flora Growth Awarded Best M&A Deal at Benzinga Cannabis Capital Conference

      Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that the Company received the Best M&A Deal award at Benzinga's 2022 Cannabis Capital Conference in Chicago. "We are honored to receive the award for Best M&A Deal at the Benzinga Cannabis Capital Conference, which recognizes our strategic M&A objectives including acquiring products, expertise, expanding distribution, and customers," said Luis Merchan, Chairman and CEO of Flora. Flora completed the acquisition of JustCBD in February 2022, and it immediately offered the Company an established CPG brand with a por

      9/13/22 7:05:00 AM ET
      $FLGC
      Biotechnology: Pharmaceutical Preparations
      Health Care